Comprehensive genomic profiling of a metastatic small cell lung carcinoma with a complete and long-term response to atezolizumab: A case report

• Published in: Respiratory medicine case reports Vol. 45; p. 101920
• Main Authors: Tomic, Kresimir, Karan Krizanac, Dragana, Skenderi, Faruk, Krpina, Kristina, Carapina Bilic, Andrea, Galic, Kristina, Gatalica, Zoran, Vranic, Semir
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01-01-2023; Elsevier
• Subjects: Atezolizumab; Case Report; Genomic profiling; Immunotherapy; Lung cancer; Small cell lung cancer; Small cell lung cancer; Genomic profiling; Lung cancer; Immunotherapy; Atezolizumab
• ISSN: 2213-0071; 2213-0071
• DOI: 10.1016/j.rmcr.2023.101920

Small cell lung cancer (SCLC) is a highly aggressive malignancy with a poor outcome. We present the case of a 57-year-old male patient with extensive-stage (ES-SCLC) treated with chemotherapy and atezolizumab. A complete response was achieved with a long remission of ∼three years. Comprehensive genomic profiling (CGP) of the tumor revealed high tumor mutation burden (13 mutations/Mb) and mutations of TP53, RB1 and ERCC4 genes. This case study confirms that a complete response to chemoimmunotherapy may be achieved in the case of ES-SCLC. It further provides the additional value of CGP and predictive testing in the management of ES-SCLC.